Secondary Bacterial Pneumonia Following Influenza

Introduction to Secondary Bacterial Pneumonia

The American Thoracic Society suggests that secondary bacterial pneumonia is a life-threatening complication of influenza, particularly in patients with asthma, characterized by a biphasic illness pattern with initial improvement followed by recurrence of fever, cough, and fatigue at day 9 1, 2, 3

The European Respiratory Society notes that biphasic illness is pathognomonic for bacterial superinfection, with temporary improvement followed by clinical deterioration after 3-5 days, strongly suggesting secondary bacterial pneumonia rather than uncomplicated influenza 1, 4
Patients with chronic respiratory disease, including asthma, are at high risk for influenza-related complications, particularly bacterial pneumonia, as indicated by the American College of Chest Physicians 1, 4
Historical precedent shows that during the 1968 pandemic, S. pneumoniae (48%), S. aureus (26%), and H. influenzae (11%) were the predominant pathogens in secondary bacterial pneumonia, with staphylococcal pneumonia carrying 47% mortality versus 16% for non-staphylococcal pneumonias, according to the Infectious Diseases Society of America 1, 4

The patient should undergo immediate diagnostic workup, including chest radiograph, pulse oximetry, complete blood count, and inflammatory markers, as recommended by the American College of Physicians 3
Empiric antibiotics should be started immediately if pneumonia is suspected clinically, even before radiographic confirmation, with first-line oral regimens including co-amoxiclav or doxycycline, covering S. pneumoniae, S. aureus, and H. influenzae, as suggested by the Infectious Diseases Society of America 2, 3

Hospitalization is required for patients with CURB-65 score ≥2, bilateral chest radiograph changes, inability to maintain oral intake, or oxygen saturation <90%, as indicated by the American Thoracic Society 2, 3
Oseltamivir may still provide benefit even beyond 48 hours in severely ill patients with asthma, with a dose of 75 mg orally twice daily for 5 days, as recommended by the Centers for Disease Control and Prevention 2, 3

Patients with asthma should continue using short-acting beta-agonists as needed for bronchospasm and maintenance inhaled corticosteroids if already prescribed, as suggested by the American Academy of Allergy, Asthma, and Immunology 5
Monitoring for asthma exacerbation triggered by the bacterial infection is crucial, as indicated by the European Respiratory Society 1, 4